Big news in the hair loss industry about Hair Loss and Hair Genesis V. New studies show big results.
I was reading a new finding in the Journal “Hair, Therapy & Transplantation” where scientists at The University of Albany, Center For Functional Genomics, were working collaboratively with Advanced Restoration Technologies (ART), DBA Hair Genesis V.
Take a read below to learn how new test results show great promise for hair loss.
Their latest findings from basic science experiments undertaken to test a novel, naturally derived hair loss treatment formula developed by ART. (http://www.omicsgroup.org/journals/htthome.php)
Chronic inflammation of the hair follicle is considered a contributing factor in the onset and progression of androgenetic alopecia (AGA) also known as pattern hair loss. Thus, investigators Sridar Chittur, Brian Parr & Geno Marcovici sought to test the study material’s ability to block certain markers of localized inflammation in scalp hair through the use of a well-validated molecular technique which mimics human hair follicle gene expression. Interestingly, the research team found that the test material reduced gene expression of three inflammatory cytokines thought to be linked to pattern hair loss.
Common hair loss affects over forty million American men and twenty million American women. The hair growth treatment industry constitutes a multi-billion dollar revenue stream annually.
In addition to anti-inflammatory properties, the test composition was formulated with a subset of botanically-derived, highly potent DHT inhibitors. DHT is the most well-described trigger of common pattern hair loss in women as well as men. By combining potent anti-inflammatory agents with powerful DHT inhibitors the test formula was designed to offer enhanced clinical efficacy over conventional monotherapy, such as Rogaine® (minoxidil 5%) or Propecia® (1 mg. finasteride).
Lead scientist for the work Sridar Chittur, Ph.D. has been at the forefront of molecular research authoring published works ranging from degenerative mitral valve disease (DMVD), to transcriptional changes associated with oxidative stress in the mitochondria. Co-author Brian Parr, Ph.D. brings a wealth of basic science expertise to the project with a number of peer-reviewed papers describing novel gene transcription and protein expression profiles in the Wnt and Frizzled pathways.
Study co-author Geno Marcovici, Ph.D. has been active in the hair loss field for almost two decades. His research efforts include the first published clinical trial successfully testing naturally derived 5 alpha reductase inhibitors in the setting of pattern hair loss. Explaining the importance of validating ART’s proprietary formulations Marcovici notes that “[a]side from Hair Genesis V, the naturally-derived hair treatments commercially available offer little or no objective evidence that they work. On the other hand, the drug-based treatments that do work come with potentially serious negative side effects. This tends to render Hair Genesis V a unique proposition in the category.”
Marcovici, also noted “one interesting observation described in this paper establishes the utility of our compositions in the clinical environment, including the potential deployment of Hair Genesis® as an adjunctive tool in autologous hair transplant surgery”.
Hair: Therapy & Transplantation (HTT), a broad based medical journal was founded on two tenets: To publish the most exciting research with respect to the subject of hair. And also to provide a rapid turn-around time for the review and publication of scientific discoveries that are highly relevant in this rapidly emerging field.
About The Center For Functional Genomics, SUNY
The Microarray Core Facility is a component of the University Of Albany Center for Functional Genomics and was established to provide the infrastructure to enable the development of major projects that utilize DNA microarrays for large-scale analysis of gene expression. The DNA Microarray Center currently employs two technologies for gene expression analysis: Affymetrix GeneChip arrays and custom-produced spotted cDNA microarrays. Projects developed through the DNA Microarray Center have made use of Affymetrix arrays from both eukaryotic as well as prokaryotic genomes. The Facility is also currently developing specialized custom printed arrays to examine gene expression in mouse tissues as part of a NIH funded Mutant Mouse Regional Resource Center.
About Advanced Restoration Technologies Inc., DBA Hair Genesis V
Combining scientific validation with the safety of natural ingredients, ART’s product line Hair Genesis V represents a unique therapeutic platform in the hair loss treatment category. Prior to focusing on basic science research, ART established a 10-year track record as a surgical center for IRB-monitored clinical investigation, testing new drugs as well as medical devices. ART-based published studies include those undertaken on behalf of Organogenesis, Canton, MA and Procyte Corporation, Kirkland, WA. It was from this research platform that Hair Genesis V was originally conceived and created. To view hair genesis products please visit Hair Genesis V.